alexa Preparing For Phase I Unit Regulatory Inspections
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

8th World congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit
June 26-27, 2017 San Diego, USA

Sudheendra K
Syngene Clinical Development, India
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-029
Clinical research organizations and industry have seen a paradigm shift towards the regulatory inspection scenario and data integrity standards that have taken the primary focus on the rights, safety and well-being of the trial subjects. The DI standards have become one of the key attention areas for the regulatory inspections, not that the inspectors are looking for fraud and maleficence. The systems used in the research industry have become more complex in terms of metadata that is being generated across the companies. The metadata that is created in a clinical trial is enormous and the inspectors are very aware of the possible DI issues that occur from time-to-time. The functions such as user access, data backup policies, audit trail, etc. have become the focus of attention. ALCOA principle is applicable to both paper and electronic data, thereby to ensure that the DI standards are followed all the time by all the personnel involved who generate the clinical trial data. To ensure that the DI standards are maintained across the life cycle of the clinical trial, quality systems should be in place and the rigor of sustaining the checks can be on a continual mode. This will ensure that the clinical trial data generated will meet all the applicable regulatory requirements. No doubt, in the coming days, the DI requirements shall be more demanding and key focus in clinical research.

Sudheendra K has his expertise in managing the GCP quality management systems at Syngene Clinical Development in the conduct of Phase I, bioequivalence, bioavailability studies. He has hosted many international regulatory inspections such as US FDA, EMA, ANVISA, Thailand GLP at Syngene Clinical Development. He is a trained Biochemist and has been associated with GCP QMS management for the last 14+ years. He has also audited many vendors and service providers who provide support for the contract research organizations for the conduct of early phase studies. He has also audited many complex clinical trials, Phase II and Phase III trials that have been conducted at different hospital sites.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version